Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Segment Information

Schedule of research and development costs

	Three Months Ended		Three Months Ended
	March 31, 2026		March 31, 2025
	(In thousands)
Barzolvolimab/Anti-KIT Program	$	62,164	$	39,703
CDX-622		4,294		5,451
Other Programs (a)		6,543		7,460
Total R&D Expense	$	73,001	$	52,614

(a) Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs.

	Three Months Ended		Three Months Ended
	March 31, 2026		March 31, 2025
	(In thousands)
Personnel	$	15,569	$	13,600
Laboratory supplies		1,458		2,168
Facility		940		1,406
Product development (b)		50,158		32,166
Other expenses (c)		4,876		3,274
Total R&D expense	$	73,001	$	52,614

(b) Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing.

(c) Other expenses primarily include research and development consulting, insurance, licensing and software expenses.